Cristina García González

Cristina García González

Auto-generated profile, based on publicly available information

Cristina García González

Anesthesiology, University Hospital of Ourense, Ourense, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
LMLuz Canovas Martínez
Luz Canovas Martínez
NDNoelia Gago Diéguez
Noelia Gago Diéguez
JSJackeline Lucia Carrera Sieiro
Jackeline Lucia Carrera Sieiro
RDRocío López Díez
Rocío López Díez
CGCristina García González
Cristina García González
SASusana Almenara
Susana Almenara
Background: Ziconotide and morphine are intrathecal (IT) drugs approved by the FDA and EMA for the treatment of chronic pain. The aim of this study was to determine whether opioid rescue can be achieved by gradually increasing doses of ziconotide, and to establish a practical protocol for its implementation. Methods: Five patients unresponsive to IT morphine due to lack of efficacy or adverse events such as endocrine dysfunction, constipation and tolerance were selected. All had refractory, neuropathic or mixed pain. Ziconotide was gradually introduced while maintaining or reducing morphine doses in proportion to the ziconotide titration. Dose adjustments were made every 2 weeks, with a weekly ziconotide increase of 0.5 μg. Results: Of the five patients, three were female and two were male, with ages ranging from 53 to 75 years. Two had cancer (one with colon cancer and one with osteosarcoma), two had persistent spinal pain syndrome type 2, and one had spastic paraparesis. After 6 weeks of ziconotide treatment, all individuals showed a substantial reduction in daily morphine dosage (from 10 to 5.5 mg/day), which was associated with improved control of adverse events. Similarly, notable reductions were observed in pain intensity (from 8.0 to 2.5, measured by VAS) and neuropathic symptoms (from 6.0 to 2.0, measured by DN4). The most frequently improved neuropathic symptoms included tingling (4 patients), hypoesthesia to touch (3 patients), and pain evoked by brushing (3 patients). The duration of the rescue protocol ranged from 5 to 11 weeks. Conclusion: Intrathecal opioid rescue with ziconotide emerges as a viable therapeutic option for patients with refractory pain and a neuropathic component, or for those who develop adverse events associated with IT morphine. Low doses and slow titration of ziconotide may help minimize adverse events while maintaining analgesic benefit. Plain Language Summary: Ziconotide and morphine are two medications used to treat chronic pain by delivering the drugs directly into the spinal fluid. While both are approved by health authorities like the FDA and EMA, some patients have problems with morphine, such as side effects or not working well enough. This study looked at whether ziconotide could help these patients by reducing the need for morphine and controlling their pain more effectively. Five patients who did not respond well to morphine or had side effects were included in the study. The researchers gradually increased the dose of ziconotide while either keeping the morphine dose the same or reducing it. The patients’ pain and side effects were carefully monitored. The results showed that all the patients were able to significantly reduce their morphine doses, which helped to reduce unwanted side effects. At the same time, their pain levels decreased, and their neuropathic symptoms (pain caused by nerve damage) improved. The rescue period lasted from 5 to 11 weeks. In conclusion, ziconotide may be a good alternative for people who have problems with morphine or have pain that does not respond to traditional treatments. Using low doses of ziconotide and increasing them slowly helps to minimize side effects while maintaining analgesic benefit.